

# Pritesh R Patel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2544475/publications.pdf>

Version: 2024-02-01

59  
papers

310  
citations

1163117

8  
h-index

940533

16  
g-index

60  
all docs

60  
docs citations

60  
times ranked

700  
citing authors

#	ARTICLE	IF	CITATIONS
1	Strength Training to Enhance Early Recovery after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 659-669.	2.0	56
2	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1759-1765.	2.0	50
3	Tumor necrosis factor- $\alpha$ inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. <i>International Journal of Cancer</i> , 2018, 143, 1062-1071.	5.1	42
4	Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. <i>Cancer</i> , 2019, 125, 1143-1154.	4.1	14
5	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. <i>PLoS ONE</i> , 2020, 15, e0229710.	2.5	14
6	Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 855-860.	2.0	13
7	Depressive symptoms, mental health-related quality of life, and survival among older patients with multiple myeloma. <i>Supportive Care in Cancer</i> , 2020, 28, 4097-4106.	2.2	12
8	Role of Ethnicity in Clinical Outcomes of Patients with Ph-Negative Myeloproliferative Neoplasms. <i>Blood</i> , 2012, 120, 2076-2076.	1.4	12
9	Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. <i>Pharmacotherapy</i> , 2019, 39, 921-928.	2.6	8
10	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study. <i>Pharmacotherapy</i> , 2019, 39, 55-66.	2.6	8
11	PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1273-1279.	2.0	8
12	Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas. <i>Blood</i> , 2018, 132, 2280-2280.	1.4	8
13	Superior Survival in African American Patients Who Underwent Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e506-e511.	0.4	7
14	Self-reported health and survival in older patients diagnosed with multiple myeloma. <i>Cancer Causes and Control</i> , 2020, 31, 641-650.	1.8	7
15	Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma. <i>International Journal of Cancer</i> , 2020, 147, 1300-1305.	5.1	6
16	Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study. <i>JMIR Cancer</i> , 2018, 4, e12.	2.4	5
17	When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e251-e258.	0.4	4
18	Treatment of older patients with diffuse large B-cell lymphoma and mild cognitive impairment or dementia. <i>Journal of Geriatric Oncology</i> , 2019, 10, 510-513.	1.0	4

#	ARTICLE	IF	CITATIONS
19	High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment. <i>Blood</i> , 2019, 134, 3081-3081.	1.4	4
20	Total Marrow and Lymphoid Irradiation to Rescue Refractory Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 536-537.	2.0	3
21	Blockade of TNF $\alpha$ to Improve Human CD34+ Cell Repopulating Activity in Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2018, 9, 3186.	4.8	3
22	Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. <i>Medicine (United States)</i> , 2019, 98, e17960.	1.0	3
23	Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. <i>British Journal of Haematology</i> , 2020, 191, e70-e72.	2.5	3
24	A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 937-943.	4.1	3
25	Melphalan 200 Mg/m <sup>2</sup> in Patients with Renal Impairment Is Associated with Increased Short Term Toxicity but Improved Response and Longer Treatment-Free Survival. <i>Blood</i> , 2015, 126, 1998-1998.	1.4	2
26	A Case of Classic Hodgkin Lymphoma Involving the Uterine Cervix Presenting As Vaginal Spotting. <i>Cureus</i> , 2020, 12, e8889.	0.5	2
27	Chronic Opioid Use Is Highly Prevalent in Patients Undergoing Allogeneic Transplant and Impacts Long Term Outcomes. <i>Blood</i> , 2021, 138, 1823-1823.	1.4	2
28	Voriconazole-Induced Periostitis Mimicking Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-3.	0.5	1
29	Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e2118410.	5.9	1
30	Treosulphan versus busulphan: pros and cons. <i>British Journal of Haematology</i> , 2021, 195, 304-305.	2.5	1
31	Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients. <i>Blood</i> , 2018, 132, 313-313.	1.4	1
32	C75 Fatty Acid Synthesis (FAS) Inhibitor Has Potent Immunosuppressive Activity. <i>Blood</i> , 2016, 128, 2156-2156.	1.4	1
33	Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan. <i>Blood</i> , 2019, 134, 1980-1980.	1.4	1
34	Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 841-841.	1.4	1
35	Bone Marrow Transplantation in Patients With Acute Leukemia In Cuba: Results From the Last 30 Years and New Opportunities Through International Collaboration. <i>Journal of Global Oncology</i> , 2018, 4, 1-7.	0.5	0
36	My Beautiful Boy. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01560.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Linac Based Total Marrow Irradiation and Myeloablative Chemotherapy In Allogeneic Stem Cell Transplantation for High Risk Patients.. Blood, 2010, 116, 4526-4526.	1.4	0
38	Anti-Leukemic Activity Is Increased with Low Dose Busulfan and Irradiation: A Preclinical Model. Blood, 2011, 118, 4696-4696.	1.4	0
39	Favorable Responses to Novel Agents for Multiple Myeloma in African American Patients,. Blood, 2011, 118, 4213-4213.	1.4	0
40	Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd. Blood, 2012, 120, 4491-4491.	1.4	0
41	Co-Stimulatory Blockade With CTLA4-Ig Permits Transplantation Of Human Hematopoietic Stem Cells and HLA Incompatible T Cells In NOD/SCID $\beta^3$ Null (NSG) Mouse Model. Blood, 2013, 122, 1999-1999.	1.4	0
42	Genomic Signature Predicts Resistance To Busulfan In AML Cell Lines. Blood, 2013, 122, 3850-3850.	1.4	0
43	Myeloablative Fludarabine/ IV Busulfan Combined With Linac Based Intensity Modulated Total Marrow Irradiation (IM-TMI) In Allogeneic Stem Cell Transplant For High Risk Hematologic Malignancies: A Phase I Study. Blood, 2013, 122, 3285-3285.	1.4	0
44	Dual DNA Damage Repair Inhibition Synergizes with Alkylator Chemotherapy for Myeloma and Acute Leukemia. Blood, 2015, 126, 2053-2053.	1.4	0
45	Preclinical Study for the Use of Abatacept to Prevent Rejection of Allogeneic CD34+ Cells in a Xenograft Model. Blood, 2015, 126, 4271-4271.	1.4	0
46	Blood and Marrow Transplantation (BMT) in Acute Leukemia Patients in Cuba: Current Results and Future Opportunities through International Collaboration. Blood, 2016, 128, 5959-5959.	1.4	0
47	Cytopenia of Unknown Cause Post Allogeneic Stem Cell Transplant As a Predictor of Clinical Outcome. Blood, 2016, 128, 5761-5761.	1.4	0
48	In-Vitro and in-Vivo Synergistic Effect of Melphalan and Dual DNA Repair Inhibition in Multiple Myeloma. Blood, 2016, 128, 3301-3301.	1.4	0
49	Race and Socioeconomic Factors Influencing Treatment Disparities and Comparative Effectiveness in Very Elderly Patients with Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 841-841.	1.4	0
50	Racial Differences in Long-Term Risk of Venous Thromboembolism Among Older Patients Following Diagnosis and Treatment of Multiple Myeloma. Blood, 2016, 128, 2071-2071.	1.4	0
51	PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm. Blood, 2018, 132, 3319-3319.	1.4	0
52	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. Blood, 2018, 132, 4693-4693.	1.4	0
53	Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma. Blood, 2018, 132, 1888-1888.	1.4	0
54	Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays. Blood, 2018, 132, 3542-3542.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant. Blood, 2019, 134, 3310-3310.	1.4	0
56	Title is missing!. , 2020, 15, e0229710.		0
57	Title is missing!. , 2020, 15, e0229710.		0
58	Title is missing!. , 2020, 15, e0229710.		0
59	Title is missing!. , 2020, 15, e0229710.		0